|
|
||||||||
J Thorac Cardiovasc Surg 2003;125:178-183
© 2003 The American Association for Thoracic Surgery
Cardiopulmonary Support and Physiology (CSP) |
From the Departments of Cardiothoracic Surgery,a Anatomy,b and Cardiology,c University of Cologne, Cologne, Germany.
Received for publication Nov 27, 2001. Revisions requested Feb 18, 2002; revisions received Feb 25, 2002. Accepted for publication April 8, 2002. Address for reprints: Uwe Mehlhorn, MD, Professor, Department of Cardiothoracic Surgery, University of Cologne, Joseph-Stelzmann-Str 9, 50924 Cologne, Germany (E-mail: uwe.mehlhorn{at}medizin.uni-koeln.de).
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
|
(8-iosprostane)
We have recently shown, in patients undergoing CABG, that cardioplegia-induced myocardial ischemia and reperfusion activates the NO-producing enzyme constitutive NO synthase (constitutive NOS or NOS-III) in cardiac myocytes and endothelium, leading to increased NO release.
12 In addition, Hayashi and colleagues
13 demonstrated that human myocardium produces peroxynitrite during reperfusion after cardioplegic arrest. These data suggest that peroxynitrite-mediated nitrotyrosine formation caused by NOS-III activation and NO release might contribute to ROS-induced reperfusion injury after cardioplegic arrest. However, direct evidence for cardioplegia-induced reperfusion injury by ROS is still lacking. Therefore the purpose of our study was to investigate the effect of cardioplegia-induced ischemia and reperfusion on myocardial formation and distribution of nitrotyrosine as an indicator for peroxynitrite-mediated tissue injury and 8-isoprostane as an indicator for ROS-mediated lipid peroxidation.
| Material and methods |
|---|
|
|
|---|
|
LV biopsy specimens
Before CPB initiation, we collected a transmural biopsy specimen from a fat-free area of the LV anterior wall using a 14-gauge biopsy needle (Gallini, Modena, Italy). A second LV biopsy specimen was taken at the end of the extracorporeal circulation before weaning from CPB. All LV biopsy specimens were placed in 4% paraformaldehyde for 4 hours and then rinsed in 0.1 mol/L phosphate-buffered saline (PBS) solution for 24 hours, followed by storage for 12 hours in PBS solution with 18% sucrose for cryoprotection, and frozen at -80°C. Because 4% paraformaldehyde has been shown to result in optimal fixation of cyclic guanosine monophosphate (cGMP) on the cell's protein matrix,
15 we used this solution for immunohistochemical detection of the water-soluble cGMP.
Immunocytochemistry
Before immunohistochemical examination, 10-µm slices from the biopsy specimens were placed in a bathing solution of 3% H2O2 and 60% methanol PBS for 30 minutes and then permeabilized with 0.2% Triton-X 100 in 0.1 mol/L PBS. Thereafter, specimens were treated with 5% normal goat serum and 5% bovine serum albumin solution in PBS. Before each step, the sections were rinsed 3 times in PBS buffer. Incubation with primary polyclonal rabbit anti-NOS-III antibody (Biomol, Hamburg, Germany) at a dilution of 1:1500 was performed in a PBS-based solution of 0.8% bovine serum albumin and 20 mmol/L NaN3 for 12 hours at 4°C. For cGMP detection, we used a polyclonal rabbit anti-cGMP antibody (Quartett, Hamburg, Germany) at a dilution of 1:600. After rinsing with PBS, the sections were incubated with the corresponding secondary biotinylated goat anti-rabbit antibody (Vector Laboratories, Burlingame, Calif) for 1 hour at room temperature. For nitrotyrosine staining, we used a monoclonal mouse anti-nitrotyrosine antibody (Calbiochem, San Diego, Calif) at 1:400 and a secondary goat anti-mouse antibody (DAKO, Weisloch, Germany) at 1:400; for 8-isoprostane detection, a polyclonal goat anti-8-Epi-PGF2a antibody (Oxford Biomedical Research, Oxford, Mich) at 1:1500 and a secondary rabbit anti-goat antibody (DAKO, Germany) at 1:400 was used. A streptavidin-horseradish peroxidase complex was then applied as a detection system (1:100 dilution) for 1 hour. Finally, staining was developed for 3 to 5 minutes with 3,3-diaminobenzidine tetrahydrochloride in 0.05 mol/L TRIS-HCl buffer and 0.1% H2O2.
NOS-III television densitometry
All LV biopsy slices were incubated and stored under identical conditions. For intensity analysis of NOS-III immunostaining in cardiomyocytes, we measured the gray values of 50 cardiomyocytes from 10 randomly selected areas. The intensity of immunostaining was reported as the mean of measured cardiomyocyte gray value minus background gray value. The background gray value was measured at a cell-free area of the slice. For staining intensity detection, a Zeiss Axiophot microscope coupled to a 3-chip CCD camera was used, and the analysis was performed by using the Optimas 6.01 image analysis program installed on a Pentium personal computer.
cGMP semiquantitative analysis
For semiquantitative analysis of myocardial cGMP content, we used a score to differentiate between no change and clearly increased cGMP content. All specimens were independently judged by 2 investigators in a blind fashion. Any disagreement between judgements was subsequently resolved by discussion.
Nitrotyrosine and 8-isoprostane quantification
Quantitative analysis was performed on 5 randomly selected fields (66,125 µm2 per frame) of LV biopsy cross-sections. All immunohistochemically stained capillaries per field were counted with a Zeiss Axiophot microscope with a 40x oil immersion objective and expressed as number per square millimeter.
Statistical analysis
All data are presented as mean ± SD. Data were analyzed for statistical significance on an
levels of 5% by using the 2-tailed Student t test for paired samples, as implemented in the software package SASS for Windows, version 10.0. The P values reported are not adjusted for multiple testing.
| Results |
|---|
|
|
|---|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Ischemia-reperfusion injury involves both cardiac myocytes and coronary endothelial cells and appears to be a major factor contributing to perioperative myocardial damage.
16 Although the pathophysiology of ischemia-reperfusion injury is not yet fully understood, recent studies suggest that ROS mediate the reperfusion injury that characterizes metabolic, structural, and functional myocardial damage associated with experimental coronary occlusion and reperfusion.
1-3 Specifically, the role of NO and its ROS peroxynitrite (NO3-) has been studied extensively; however, the various studies have yielded conflicting data showing both protective, as well as deleterious, NO effects during reperfusion. Cardioprotective NO effects include reduction of neutrophil and platelet accumulation, inhibition of the release of cytotoxic mediators from neutrophils, direct cytoprotective effects on both endothelial cells and cardiomyocytes,
16 and potential infarct size reduction.
17 However, increased NO release has been suggested to contribute to reperfusion injury through peroxynitrite-mediated membrane nitration, DNA synthesis inhibition,
18 mitochondrial function inhibition,
19 ribonucleotide reductase inhibition,
20 and cytokine-induced myocardial contractile dysfunction.
21 These data suggest that high NO levels during reperfusion might be as deleterious as NO absence, and thus the role of NO in ischemia and reperfusion might be dose dependent.
Our and other groups' recent experimental work showed that myocardial ischemia acts as the stimulus for NOS-III activation, probably by inducing a conformational change of the enzyme, resulting in increased NO release as indicated by increased intracellular cGMP, NO's intracellular second messenger.
22,23 Similarly, we have demonstrated, in patients undergoing CABG, that cardioplegic arrest is associated with NOS-III activation and increased cGMP in both cardiac myocytes and endothelial cells, indicating increased NO formation.
12 To further elucidate the pathophysiology of NO in ischemia and reperfusion, we intended to investigate whether the increased NO release caused by NOS-III activation results in myocardial tyrosine nitration as direct evidence for tissue injury. In the present study the number of nitrotyrosine-positive capillaries was significantly increased after cardioplegia (Figure 3
), indicating peroxynitrite formation in the myocardium. This is in agreement with recent work by Hayashi and colleagues,
13 who demonstrated transcoronary peroxynitrite production during reperfusion in patients subjected to cardioplegic arrest. These data suggest that peroxynitrite-mediated nitrotyrosine formation caused by NOS-III activation and increased NO release contributes to ROS-induced myocardial injury after cardioplegic arrest and CPB.
In addition to peroxynitrite, other ROS, including hydroxyl radical (OH-), superoxide radical (O2-), and hydrogen peroxide (H2O2), have been suggested to be involved in ischemia-reperfusion injury.
1-3 One novel marker for ROS-mediated membrane lipid oxidation is 8-isoprostane, the stable end product of arachidonic acid oxidation.
8,11 Investigators have determined 8-isoprostane as a marker of oxidative stress in urine
1 or blood
24 of patients subjected to percutaneous transluminal coronary angioplasty with acute myocardial infarction; however, myocardial 8-isoprostane formation and distribution caused by cardioplegia have not been studied. In the present study the number of 8-isoprostane-positive capillaries in human myocardium was significantly increased at the end of CPB (Figure 4
). These data provide direct evidence for the contribution of ROS-mediated membrane lipid oxidation to ischemia-reperfusion injury in patients subjected to intermittent cold-blood cardioplegia. Interestingly, 8-isoprostane and nitrotyrosine formation were mainly confined to coronary endothelium, and only little staining was observed in cardiac myocytes (Figure 1
). This is probably because of the high cardiac myocyte superoxide dismutase concentration,
25 resulting in only little myocyte ROS, and thus 8-isoprostane, as well as nitrotyrosine, formation, even in the presence of increased NO as NO, requires O2- to form NO3-.
16
Functional implications
The functional correlate of ROS-mediated tissue injury is myocardial stunning.
2,3 Recent experimental studies have shown that peroxynitrite production caused by increased NO release is associated with irreversible cardiac function impairment
26 and higher mortality after coronary occlusion
27 and might be involved in cardiac apoptosis initiation.
10 Gupte and Okada
28 recently demonstrated that ROS mediate LV dysfunction through peroxynitrite production that can be attenuated by NOS inhibition. In addition, 8-isoprostane has been shown to induce coronary vasoconstriction associated with lactate production and contractile dysfunction.
29 This coronary vasoconstriction persisted even after removal of the ROS stimulus and might thus contribute to the no-reflow phenomenon during reperfusion.
30 In the present study global LV ejection fraction, as measured by means of FAC, was unchanged at 10 to 15 minutes after separation from CPB but was slightly decreased at 4 hours after CPB. Because these patients received continuous infusion of 3.9 ± 1.0 µg·min-1·kg-1 dopamine after CPB, this mild LV dysfunction could reflect the functional ischemia-reperfusion injury associated with the structural LV myocardial changes we observed. However, other factors, including changed loading conditions or decreased endogenous catecholamines, could also have affected LV performance.
Limitations of the study
Because we did not include a treatment group (ie, addition of a radical scavenger or NOS inhibitor) in our study, the present findings have to be regarded as preliminary observations. Furthermore, ROS are only one aspect in the mutifactorial process of ischemia-reperfusion injury, which involves several factors, such as physical, metabolic, and immunologic components. Thus the immunohistochemical changes we observed might not be causally related to injury directly caused by ischemia and reperfusion. Further studies will have to show that pharmacologic interventions can decrease the tissue content of ROS-induced changes and that this will be associated with improved cardiac performance to prove the clinical relevance of ROS. In addition, the data of the present study do not allow us to separate changes induced by CPB from those caused by cardioplegia and reperfusion. Thus CPB itself could have been the source of some or all ROS-mediated changes we observed. However, this is unlikely because we have previously shown that LV NOS-III and cGMP were not activated when using continuous antegrade coronary perfusion with normothermic CPB blood enriched with the ß-blocker esmolol, a nonischemic myocardial protection method during aortic crossclamping.
12 Together with the experimental data from our and other groups,
22,23 these data suggest that ischemia acts as a stimulus for NOS-III activation. Future studies are required to further elucidate the effect of CPB, cardioplegia, and reperfusion on NOS activity regulation and ROS formation, as well as their effects on tissues.
In conclusion, the data of the present study for the first time provide direct evidence for ROS-induced myocardial injury after ischemia and reperfusion in patients subjected to cardioplegia and CPB. These findings suggest a rational basis for investigation of ROS scavengers, selective NOS inhibition, or both as adjuncts to reperfusion strategies. Specifically, direct myocardial nitrotyrosine and 8-isoprostane detection in the experimental setting might be used to provide a rational basis for dose selection before clinical evaluation of antioxidant reperfusion strategies.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
P. Pacher and C. Szabo Role of the Peroxynitrite-Poly(ADP-Ribose) Polymerase Pathway in Human Disease Am. J. Pathol., July 1, 2008; 173(1): 2 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ramzy, L. C. Tumiati, E. Tepperman, R. Sheshgiri, J. Jackman, M. Badiwala, and V. Rao Dual immunosuppression enhances vasomotor injury: Interactive effect between endothelin-1 and nitric oxide bioavailability. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 938 - 944. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Mueed, T. Tazzeo, C. Liu, E. Pertens, Y. Zhang, I. Cybulski, L. Semelhago, J. Noora, A. Lamy, K. Teoh, et al. Isoprostanes constrict human radial artery by stimulation of thromboxane receptors, Ca2+ release, and RhoA activation J. Thorac. Cardiovasc. Surg., January 1, 2008; 135(1): 131 - 138. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Pacher, J. S. Beckman, and L. Liaudet Nitric Oxide and Peroxynitrite in Health and Disease Physiol Rev, January 1, 2007; 87(1): 315 - 424. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.B. Corcoran, A. Engel, H. Sakamoto, A. O'Shea, S. O'Callaghan-Enright, and G. D. Shorten The effects of propofol on neutrophil function, lipid peroxidation and inflammatory response during elective coronary artery bypass grafting in patients with impaired ventricular function Br. J. Anaesth., December 1, 2006; 97(6): 825 - 831. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ramzy, V. Rao, L. C. Tumiati, N. Xu, S. Miriuka, D. Delgado, and H. J. Ross Role Of Endothelin-1 and Nitric Oxide Bioavailability in Transplant-Related Vascular Injury: Comparative Effects of Rapamycin and Cyclosporine Circulation, July 4, 2006; 114(1_suppl): I-214 - I-219. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. McGuinness, T.G. Neilan, A. Sharkasi, D. Bouchier-Hayes, and J.M. Redmond Myocardial protection using an omega-3 fatty acid infusion: Quantification and mechanism of action J. Thorac. Cardiovasc. Surg., July 1, 2006; 132(1): 72 - 79. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Knott, J. Sun, Y. Lei, M.-G. Ryou, A. H. Olivencia-Yurvati, and R. T. Mallet Pyruvate Mitigates Oxidative Stress During Reperfusion of Cardioplegia-Arrested Myocardium. Ann. Thorac. Surg., March 1, 2006; 81(3): 928 - 934. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Bjerrum, M. J. Perko, and B. Beck Myocardial oxygen tension during surgical revascularization: A clinical comparison between blood cardioplegia and crystalloid cardioplegia Eur. J. Cardiothorac. Surg., February 1, 2006; 29(2): 181 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Xia, K.-H. Kuo, D. V. Godin, M. J. Walker, M. C. Y. Tao, and D. M. Ansley 15-F2t-isoprostane exacerbates myocardial ischemia-reperfusion injury of isolated rat hearts Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1366 - H1372. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Caputo, S. Bays, C. A. Rogers, A. Pawade, A. J. Parry, S. Suleiman, and G. D. Angelini Randomized Comparison Between Normothermic and Hypothermic Cardiopulmonary Bypass in Pediatric Open-Heart Surgery Ann. Thorac. Surg., September 1, 2005; 80(3): 982 - 988. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Knott, M.-G. Ryou, J. Sun, A. Heymann, A. B. Sharma, Y. Lei, M. Baig, R. T. Mallet, and A. H. Olivencia-Yurvati Pyruvate-fortified cardioplegia suppresses oxidative stress and enhances phosphorylation potential of arrested myocardium Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1123 - H1130. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Mallet, J. Sun, E. M. Knott, A. B. Sharma, and A. H. Olivencia-Yurvati Metabolic Cardioprotection by Pyruvate: Recent Progress Experimental Biology and Medicine, July 1, 2005; 230(7): 435 - 443. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. M. Fischer, P. Tossios, A. Huebner, H. J. Geissler, W. Bloch, and U. Mehlhorn Myocardial apoptosis prevention by radical scavenging in patients undergoing cardiac surgery J. Thorac. Cardiovasc. Surg., July 1, 2004; 128(1): 103 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. M. Fischer, C. S. Cox Jr, S. J. Allen, R. H. Stewart, U. Mehlhorn, and G. A. Laine The antioxidant N-acetylcysteine preserves myocardial function and diminishes oxidative stress after cardioplegic arrest J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1483 - 1488. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Tossios, W. Bloch, A. Huebner, M. R. Raji, F. Dodos, O. Klass, M. Suedkamp, S.-M. Kasper, M. Hellmich, and U. Mehlhorn N-acetylcysteine prevents reactive oxygen species-mediated myocardial stress in patients undergoing cardiac surgery: Results of a randomized, double-blind, placebo-controlled clinical trial J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1513 - 1520. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. M. Fischer, O. Klass, U. Stock, J. Easo, H. J. Geissler, J. H. Fischer, W. Bloch, and U. Mehlhorn Cardioplegic arrest induces apoptosis signal-pathway in myocardial endothelial cells and cardiac myocytes Eur. J. Cardiothorac. Surg., June 1, 2003; 23(6): 984 - 990. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |